Injured Alberta workers and first responders with accepted PTSD (post-traumatic stress disorder) or chronic pain claims may be eligible for ketamine-assisted therapy under WCB Alberta's (Workers' Compensation Board of Alberta) Pharmaceutical Ketamine and Esketamine procedure. Coverage is evaluated case-by-case, is not automatic, and requires a prior-authorization request from a treating specialist. This article explains who qualifies, what the evidence shows, and how the process works.

Key takeaways

WCB Alberta has a documented procedure (Procedure 4-12) covering ketamine and esketamine for compensable psychiatric and chronic pain conditions, evaluated case-by-case.

Only a treating specialist, such as a neurologist, psychiatrist, physiatrist, or chronic pain specialist, may submit a prior-authorization request using WCB Form C1520.

Alberta's Bill 30 (2018) creates a presumption that PTSD diagnosed in designated first responders is work-related, which accelerates the underlying claim but does not automatically approve specific treatments.

A 2023 randomized controlled trial (Feder et al.) found that 67% of participants with chronic PTSD who received repeated IV ketamine infusions met the definition of treatment responder, compared with 20% in the active placebo group [Feder 2023].

Psilocybin and MDMA are not formally listed on WCB Alberta's formulary; access is through Health Canada's Special Access Program (SAP) on a case-by-case basis with no guarantee of approval.

The CPSA's (College of Physicians and Surgeons of Alberta) March 2026 guidance requires intravenous ketamine to be delivered in a CPSA-accredited Non-Surgical Health Facility (NSHF); other routes may be provided in qualifying community settings.

Does WCB Alberta cover psychedelic-assisted therapy?

WCB Alberta evaluates ketamine and esketamine treatment requests through its Pharmaceutical Ketamine and Esketamine procedure (Procedure 4-12 of the WCB Procedures Manual) [WCB Alberta 2024]. The procedure covers psychiatric and chronic pain conditions that result from a compensable injury, including treatment-resistant depression and other DSM-5 psychiatric diagnoses. Coverage is assessed case-by-case. It is not automatically provided, and approval requires clinical justification from a treating specialist.

The process is initiated by the treating specialist, not by the worker or the clinic. The specialist must submit a written prior-authorization request using Application Form C1520 and document that conventional treatments have been tried and have not produced sufficient clinical benefit. WCB refers the request to an internal Medical Consultant and may recommend a Psychiatric Expedited Specialist Consultation before rendering a decision.

Psilocybin and MDMA are not formally listed on WCB Alberta's formulary. For compensable PTSD, access to these substances is through Health Canada's Special Access Program (SAP) on a case-by-case basis, and SAP approval has declined significantly since 2025 [PsyCan 2025]. The practical 2026 pathway for WCB-covered psychedelic-assisted therapy in Alberta involves ketamine and esketamine specifically.

For a cross-provincial comparison of workers' compensation coverage for psychedelic-assisted therapy, see the workers' compensation and psychedelic-assisted therapy guide for Canada.

Who qualifies: first responders, injured workers, and compensable conditions

Workers eligible for WCB Alberta ketamine prior-authorization include those with a compensable diagnosis of treatment-resistant depression, PTSD, or chronic pain conditions resulting from a workplace injury. Additional eligibility criteria in the WCB procedure include [WCB Alberta 2024]:

Age 18 or older
No history of a primary psychotic disorder
Able to provide informed consent
Not pregnant or breastfeeding
No known allergy to ketamine

First responders and Alberta's Bill 30

Alberta's Workers' Compensation Amendment Act, 2018 (Bill 30) established a legal presumption that PTSD diagnosed in designated first responders is work-related, unless the contrary is proven [Bill 30 AB 2018]. This shifted the burden of proof and accelerated access to WCB benefits for this population. Designated occupations covered by Alberta's presumptive PTSD legislation include:

Police officers and peace officers
RCMP personnel
Paramedics and emergency medical technicians
Firefighters (municipal and volunteer)
Correctional officers
Nurses and paramedics in specific healthcare settings
Emergency dispatchers and 911 operators

Important framing: Bill 30 presumptive eligibility applies to the underlying PTSD diagnosis and WCB claim acceptance. It does not automatically approve specific treatments such as ketamine-assisted therapy. A prior-authorization request via Form C1520 is still required. The presumptive eligibility removes the burden on the worker to prove work-relatedness of their PTSD, which can meaningfully speed up claim acceptance and access to the treatment pathway.

Workers outside the designated first-responder occupations who have compensable PTSD or chronic pain may also pursue WCB ketamine prior-authorization. Their claims require more documentation of work-relatedness but are reviewed under the same Procedure 4-12 framework.

The evidence base: ketamine for PTSD and chronic pain

Ketamine for PTSD

The most rigorous published evidence for ketamine in PTSD comes from a randomized controlled trial by Feder and colleagues [Feder 2023], published in the American Journal of Psychiatry. In this trial (N=30), participants with chronic PTSD were randomly assigned to receive six infusions of IV ketamine (0.5 mg/kg) or midazolam (an active placebo) over two consecutive weeks. At week 2, PTSD symptom severity on the CAPS-5 scale was 11.88 points lower in the ketamine group than in the midazolam group (effect size d=1.13, 95% CI 0.36 to 1.91). Among the ketamine group, 67% were treatment responders compared with 20% in the midazolam group [Feder 2023].

A 2024 meta-analysis and systematic review of 11 studies (384 military members) evaluated ketamine for depression, PTSD, and chronic pain in veteran and active-duty populations [Liu 2024]. The pooled effect size was g=1.76 (95% CI 1.39 to 2.13), with a PTSD-specific pooled effect of g=1.34. The authors note significant publication bias and recommend cautious interpretation [Liu 2024].

Ketamine for PTSD in veterans and first responders specifically

A Phase 2 clinical trial by Mithoefer and colleagues [Mithoefer 2018], published in The Lancet Psychiatry, tested MDMA-assisted psychotherapy in military veterans, firefighters, and police officers with chronic PTSD. Active-dose MDMA (75 mg and 125 mg) with adjunctive psychotherapy significantly reduced PTSD symptoms compared with a 30 mg active control. At the 12-month follow-up, the mean CAPS-IV score was 38.8, down from a baseline of 87.1 (p<0.0001) [Mithoefer 2018]. This population of veterans and first responders most closely maps to the Alberta WCB audience.

Ketamine for chronic pain (CRPS and neuropathic pain)

For compensable chronic pain, ketamine has demonstrated efficacy in CRPS and neuropathic pain conditions. A narrative review of 15 CRPS studies found an immediate pain relief rate of 69% and a 1-to-3-month pain relief rate of 58% [Gauthier 2023]. A 2023 systematic review and meta-analysis of IV ketamine for chronic pain found a statistically significant reduction in pain scores (mean difference -1.05 on a standard pain scale; 95% CI -1.72 to -0.39; p=0.002) [Odutola 2023].

The Edmonton community ketamine programme, documented by Swainson and colleagues (published January 2024 in Frontiers in Psychiatry), provided a practical framework for ketamine delivery in Alberta's public healthcare system [Chrenek 2024]. The initial cohort (50 patients with ultra-resistant depression) showed a 44% response rate within 8 IV treatments. The Edmonton protocols formed the basis for a broader provincial IV ketamine protocol for Alberta.

For an in-depth review of the evidence supporting ketamine for PTSD specifically, see ketamine therapy for PTSD. For chronic pain evidence, see ketamine therapy for chronic pain.

Key stat: In the Feder 2023 PTSD trial, 67% of participants in the ketamine group met the treatment-responder threshold compared with 20% in the active placebo group, with a large effect size (d=1.13) [Feder 2023]. Study limitations: small sample (N=30); single site; follow-up limited to two weeks post-treatment.

Psilocybin and MDMA: the SAP pathway for compensable PTSD

Psilocybin and MDMA carry the strongest Phase 3 RCT evidence for PTSD. Mitchell and colleagues published two confirmatory Phase 3 trials of MDMA-assisted therapy. In the MAPP1 trial (N=90), 67% of participants in the MDMA group no longer met the diagnostic criteria for PTSD versus 32% in the placebo group (p<0.0001) [Mitchell 2021]. The MAPP2 confirmatory trial (N=104) replicated these results in a diverse population with comorbidities including dissociation, depression, and substance use history [Mitchell 2023].

Despite this evidence, neither psilocybin nor MDMA is formally listed on WCB Alberta's formulary. Patient access to these substances for therapeutic use requires Health Canada's Special Access Program (SAP) authorization, granted case-by-case [Health Canada SAP]. SAP approval is not guaranteed. Approval rates declined significantly in 2025, with approximately half as many approvals granted under the current federal government compared with the prior year [PsyCan 2025]. The realistic WCB-covered pathway for compensable PTSD in Alberta in 2026 remains ketamine and esketamine specifically.

Patients interested in psilocybin- or MDMA-assisted therapy under SAP who also have a WCB claim should discuss both pathways with their treating physician. ATMA CENA supports SAP application preparation for eligible patients who wish to pursue this route alongside or separately from their WCB claim.

The WCB Alberta prior-authorization process: step by step

The process from first call to treatment follows these stages [WCB Alberta 2024; ATMA CENA clinical process]:

Establish compensable diagnosis. For first responders, Bill 30 presumptive eligibility accelerates this step. The worker files a WCB claim and the treating physician documents the diagnosis according to DSM-5 criteria.
Document conventional treatment failures. The treating specialist records trials of standard-of-care treatments (pharmacotherapy, evidence-based psychotherapy such as CBT or EMDR, or other indicated modalities) that have not produced sufficient improvement.
Identify a treating specialist willing to prescribe ketamine. The prescribing physician must be a neurologist, psychiatrist, physiatrist, or chronic pain specialist. Family physicians may prescribe non-IV ketamine in consultation with a psychiatrist under CPSA March 2026 guidance.
Submit prior-authorization request (Form C1520). The treating specialist submits the written request to WCB Alberta. The request must document the compensable diagnosis, prior treatment failures, proposed treatment protocol, and clinical rationale.
WCB medical review. All requests are reviewed by an internal WCB Medical Consultant. WCB may recommend a Psychiatric Expedited Specialist Consultation before making a decision.
Approval decision. WCB communicates a written decision to both the worker and the treating specialist. Initial approvals cover treatment for up to 3 months, with medication reports required every 3 months during the approved period.
Treatment begins. If approved, treatment is delivered in a qualifying clinical setting under physician oversight and in compliance with CPSA accreditation requirements.

Alberta's regulatory framework: CPSA standards and PAPT licensing

Alberta is the first province in Canada to have established formal regulatory infrastructure for psychedelic-assisted psychotherapy. Providers must hold:

Alberta PAPT facility licence under the Mental Health Services Protection Act and the Mental Health Services Protection Regulation
CPSA facility accreditation for psychedelic-assisted psychotherapy, which requires a structured facility assessment

The CPSA published updated ketamine prescribing, administration, and oversight expectations in March 2026 [CPSA 2026]. Key requirements:

Intravenous (IV) ketamine must be administered in a CPSA-accredited Non-Surgical Health Facility (NSHF) with an appropriately qualified clinical team.
Non-IV routes (oral, sublingual, intranasal, intramuscular) may be provided in qualifying community clinical settings, within the prescriber's scope of practice, in consultation with a psychiatrist.
The guidance does not create new prescribing authority, approve new indications, or replace clinical judgment.
Ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, anxiety, and chronic pain is off-label.

Watch out: Not every clinic offering "ketamine therapy" in Alberta holds full CPSA PAPT accreditation or the Alberta facility licence required for psychedelic-assisted psychotherapy specifically. Workers pursuing WCB-covered treatment should confirm facility accreditation as part of their due diligence. ATMA CENA's licensing and accreditation page provides current documentation.

How ATMA CENA works with WCB Alberta case managers and treating physicians

ATMA CENA's role in a WCB Alberta treatment pathway is as the clinical delivery partner for ketamine-assisted therapy — not the prior-authorization decision-maker. WCB decides coverage; the treating specialist submits the request; ATMA CENA delivers the therapy.

In practice, ATMA CENA's clinical process for WCB-referred workers includes:

Intake and screening: An ATMA CENA practitioner reviews the clinical history, treatment records, and compensable diagnosis to confirm appropriateness for ketamine-assisted therapy and to support the treating specialist's prior-authorization documentation.
Coordination with existing treaters: ATMA CENA works alongside, not instead of, the worker's current psychiatrist, psychologist, or counsellors. This is particularly important for first responders who may have existing mental-health-care relationships through occupational health, EAP programmes, or WSIB-affiliated providers.
Documentation support: ATMA CENA can prepare clinical documentation of treatment history and rationale to support the treating specialist's C1520 submission. ATMA CENA does not submit on behalf of the worker; only the treating specialist may do so.
Treatment delivery: If WCB approves, ATMA CENA delivers the approved treatment programme (preparation sessions, medicine sessions, integration sessions) in the Edmonton or Calgary clinic.

For workers whose WCB claim is under appeal or whose prior-authorization is denied, ATMA CENA can assist with documentation that may support an appeal, in coordination with the treating specialist and, where applicable, legal counsel.

Frequently asked questions

Does WCB Alberta cover psychedelic therapy?

WCB Alberta has a documented procedure (Procedure 4-12) covering ketamine and esketamine for compensable psychiatric and chronic pain conditions, evaluated on a case-by-case basis. Coverage is not automatic. Psilocybin and MDMA are not formally listed on the WCB Alberta formulary; access requires Health Canada SAP authorization separately [WCB Alberta 2024].

Which WCB conditions qualify for ketamine prior-authorization in Alberta?

The WCB Alberta procedure covers "psychiatric conditions and/or chronic pain conditions resulting from a compensable injury," including treatment-resistant depression and DSM-5 psychiatric diagnoses. Workers must be 18 or older, free from primary psychotic disorder history, capable of informed consent, not pregnant, and have no ketamine allergy [WCB Alberta 2024].

Who are the designated first responders under Alberta's Bill 30?

Designated first responders eligible for presumptive PTSD coverage under Alberta's Bill 30 (2018) include police officers, RCMP, paramedics, firefighters (municipal and volunteer), correctional officers, nurses in specified settings, and emergency dispatchers [Bill 30 AB 2018].

Does presumptive PTSD automatically cover ketamine therapy?

No. Bill 30 presumptive eligibility accelerates the underlying PTSD claim acceptance (removing the burden to prove work-relatedness) but does not automatically approve specific treatments. Ketamine prior-authorization via Form C1520 is still required after the underlying claim is accepted [WCB Alberta 2024].

How long does WCB prior-authorization take?

WCB Alberta reviews are typically communicated to the worker and treating specialist within a few weeks of application, though timelines vary based on clinical complexity and whether a Psychiatric Expedited Specialist Consultation is recommended. ATMA CENA's intake screening is typically completed within one week of the first call.

Can ATMA CENA submit the WCB prior-authorization request on my behalf?

No. WCB Alberta's procedure requires that prior-authorization requests be submitted by the treating specialist, specifically a neurologist, psychiatrist, physiatrist, or chronic pain specialist using Form C1520 [WCB Alberta 2024]. ATMA CENA can assist with clinical documentation to support that submission but cannot act as the submitting party.

What if WCB denies the prior-authorization request?

Workers may appeal a WCB denial through WCB Alberta's internal dispute resolution process. Additional clinical justification, documentation of further treatment failures, or specialist consultation reports may support an appeal. Specialized workers' compensation lawyers and the Office of the Worker Adviser (Alberta) can provide guidance on the appeal process.

Does WCB cover psilocybin or MDMA therapy in Alberta?

No. Psilocybin and MDMA are not formally listed on WCB Alberta's formulary. Access is through Health Canada's Special Access Program on a case-by-case basis. SAP approval is not guaranteed and declined significantly in 2025 [PsyCan 2025; Health Canada SAP].

Is ATMA CENA's Edmonton or Calgary clinic an approved WCB provider?

Does WCB cover the psychotherapy component (preparation, integration sessions) as well as the medication?

Coverage architecture is case-by-case. WCB Alberta typically authorizes medications and may separately authorize physician-supervised psychotherapy components. The specific scope of what is covered in an approved treatment episode depends on the treating specialist's submitted protocol and WCB's authorization decision. Our clinical team discusses this clearly during the intake call.

What does ketamine-assisted therapy actually involve?

Ketamine-assisted therapy at ATMA CENA involves three phases: preparation sessions (typically two to four appointments to establish therapeutic context and safety planning), medicine sessions (ketamine administered in a supervised clinical setting, typically lasting 40 to 90 minutes depending on the route of administration), and integration sessions (processing the experience and translating insights into ongoing therapeutic work). The total programme length depends on the WCB-approved protocol.

What is ATMA CENA's location and contact for WCB Alberta enquiries?

Compliance notes

Ketamine off-label framing (required per CPSA and writing standards)

Ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, anxiety, and chronic pain is off-label and regulated by the College of Physicians and Surgeons of Alberta (CPSA). The CPSA's March 2026 guidance requires intravenous (IV) ketamine to be administered in a CPSA-accredited Non-Surgical Health Facility (NSHF). Non-IV routes (oral, sublingual, intranasal, intramuscular) may be provided in qualifying community clinical settings by a qualified prescriber in consultation with a psychiatrist. All ketamine-assisted therapy at ATMA CENA is delivered under physician oversight and in compliance with current CPSA standards [CPSA 2026].

Psilocybin and MDMA framing (required per Health Canada SAP notice)

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada's Special Access Program (SAP). SAP approval is granted on a case-by-case basis and is not guaranteed. Psilocybin SAP is primarily approved for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA SAP is primarily approved for adults with PTSD. Approval rates declined significantly in 2025 [PsyCan 2025; Health Canada SAP].

Sources

WCB Alberta (2024). Ketamine or Esketamine Treatment Decision Procedure (Procedure 4-12). Workers' Compensation Board of Alberta. https://www.wcb.ab.ca/about-wcb/procedures-manual/pharmaceutical-ketamine-and-esketamine.html
Government of Alberta (2018). Workers' Compensation Amendment Act, 2018 (Bill 30) — presumptive PTSD for first responders. https://www.rankandfile.ca/albertas-bill-30-psychological-injuries-deeming-and-rt/
CPSA — College of Physicians and Surgeons of Alberta (2026). Ketamine prescribing, administration and oversight expectations. March 2026. https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
CPSA — College of Physicians and Surgeons of Alberta (2021). Clinical Toolkit: Ketamine and Esketamine. https://cpsa.ca/resources/ketamine-toolkit/
Health Canada (2022). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
PsyCan (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
Feder, A. et al. (2023). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry. https://pubmed.ncbi.nlm.nih.gov/37404970/
Mitchell, J.M. et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://pubmed.ncbi.nlm.nih.gov/33972795/
Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473–2480. https://pubmed.ncbi.nlm.nih.gov/37709999/
Mithoefer, M.C. et al. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for PTSD in military veterans, firefighters, and police officers. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
Chrenek, C., Duong, B., Khullar, A. et al. (Swainson, J.) (2024). Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Frontiers in Psychiatry, 14:1283733. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full
Odutola, O. et al. (2023). IV ketamine infusion therapy for chronic pain: A systematic review and meta-analysis. Medicine Advances. https://onlinelibrary.wiley.com/doi/full/10.1002/med4.45
Liu, J.J.W., Ein, N., Gervasio, J. et al. (2024). Ketamine in the effective management of chronic pain, depression, and posttraumatic stress disorder for Veterans: A meta-analysis and systematic review. Frontiers in Psychiatry. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1338581/full

Workers' Compensation and Psychedelic-Assisted Therapy in Canada — cross-provincial comparison
Insurance Coverage for Psychedelic-Assisted Therapy in Canada — private and group insurance coverage overview
Ketamine Therapy for PTSD — evidence deep-dive
Ketamine Therapy for Chronic Pain — chronic pain evidence
Psychedelic-Assisted Therapy in Edmonton — Edmonton clinic access
Psychedelic-Assisted Therapy in Calgary — Calgary clinic access

Last updated: 2026-05-06. This article is reviewed every 3 months given time-sensitive regulatory and coverage information.

WCB Alberta Psychedelic Therapy: Coverage, Evidence, and the Prior-Auth Process (2026)

Coverage rules differ by payer